SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF CATEGORY 1 INNVOATIVE DRUG UNECRITNIB FUMARATE CAPSULES "UNECRITINIB (TQ-B3101)"
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - 52 RESEARCH RESULTS WILL BE PRESENTED AT 2024 ASCO ANNUAL MEETING
SINO BIOPHARM: NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS
SINO BIOPHARM: NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS
SINO BIOPHARM: FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING (OR ANY ADJOURNMENT THEREOF)
SINO BIOPHARM: 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - CATEGORY 1 INNOVATIVE DRUG "TQA3038 (siRNA)" COMPLETED PHASE I CLINICAL STUDY
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
SINO BIOPHARM: NEXT DAY DISCLOSURE RETURN
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - CATEGORY 1 INNOVATIVE DRUG "ROVADICITINIB (TQ05105)" OBTAINED POSITIVE RESULTS IN KEY CLINICAL RESEARCH FOR REGISTRATION
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
SINO BIOPHARM: NEXT DAY DISCLOSURE RETURN
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - PRESENTATION OF THE PHASE II CLINICAL STUDY DATA ON KRAS G12C INHIBITOR "GARSORASIB TABLET (D-1553)"
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - DATA OF 6 STUDIES REGARDING "ANLOTINIB HYDROCHLORIDE CAPSULES", "TQB2916 (CD40 AGONIST)" AND "FHND6091 (PROTEASOME INHIBITOR)" WERE PRESENTED AT 2024 AACR
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - ENTER INTO STRATEGIC PARTNERSHIP WITH BOEHRINGER INGELHEIM ON INNOVATIVE ONCOLOGY PORTFOLIO IN CHINA
SINO BIOPHARM: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2024
SINO BIOPHARM: FINAL DIVIDEND FOR 2023
No Data